Literature DB >> 28969354

Paradigms for Assessing Hedonic Processing and Motivation in Humans: Relevance to Understanding Negative Symptoms in Psychopathology.

Deanna M Barch1, James M Gold2, Ann M Kring3.   

Abstract

Clinicians and researchers have long known that one of the debilitating aspects of psychotic disorders is the presence of "negative symptoms," which involve impairments in hedonic and motivational function, and/or alterations in expressive affect. We have a number of excellent clinical tools available for assessing the presence and severity of negative symptoms. However, to better understand the mechanisms that may give rise to negative symptoms, we need tools and methods that can help distinguish among different potential contributing causes, as a means to develop more targeted intervention pathways. Using such paradigms is particularly important if we wish to understand whether the causes are the same or different across disorders that may share surface features of negative symptoms. This approach is in line with the goals of the Research Diagnostic Criteria Initiative, which advocates understanding the nature of core dimensions of brain-behavior relationships transdiagnostically. Here we highlight some of the emerging measures and paradigms that may help us to parse the nature and causes of negative symptoms, illustrating both the research approaches from which they emerge and the types of constructs that they can help elucidate.
© The Author 2017. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  amotivation; anhedonia; assessment; negative symptoms; psychopathology; schizophrenia

Mesh:

Year:  2017        PMID: 28969354      PMCID: PMC5472132          DOI: 10.1093/schbul/sbx063

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  61 in total

Review 1.  A new perspective on anhedonia in schizophrenia.

Authors:  Gregory P Strauss; James M Gold
Journal:  Am J Psychiatry       Date:  2012-04       Impact factor: 18.112

2.  Prefrontal cortex mediation of cognitive enhancement in rewarding motivational contexts.

Authors:  Koji Jimura; Hannah S Locke; Todd S Braver
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

3.  Neural Correlates of Reward Processing in Depressed and Healthy Preschool-Age Children.

Authors:  Andy C Belden; Kelsey Irvin; Greg Hajcak; Emily S Kappenman; Danielle Kelly; Samantha Karlow; Joan L Luby; Deanna M Barch
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-10-04       Impact factor: 8.829

4.  Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.

Authors:  Jack J Blanchard; Ann M Kring; William P Horan; Raquel Gur
Journal:  Schizophr Bull       Date:  2010-09-22       Impact factor: 9.306

5.  Speech deficits in serious mental illness: a cognitive resource issue?

Authors:  Alex S Cohen; Jessica E McGovern; Thomas J Dinzeo; Michael A Covington
Journal:  Schizophr Res       Date:  2014-11-17       Impact factor: 4.939

6.  Computerized measurement of negative symptoms in schizophrenia.

Authors:  Alex S Cohen; Murray Alpert; Tasha M Nienow; Thomas J Dinzeo; Nancy M Docherty
Journal:  J Psychiatr Res       Date:  2007-10-24       Impact factor: 4.791

7.  Negative symptoms of schizophrenia are associated with abnormal effort-cost computations.

Authors:  James M Gold; Gregory P Strauss; James A Waltz; Benjamin M Robinson; Jamie K Brown; Michael J Frank
Journal:  Biol Psychiatry       Date:  2013-02-07       Impact factor: 13.382

8.  Durable improvements in Wisconsin Card Sorting Test performance in schizophrenic patients.

Authors:  M G Vollema; G J Geurtsen; A J van Voorst
Journal:  Schizophr Res       Date:  1995-08-15       Impact factor: 4.939

Review 9.  Mapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysis.

Authors:  Bei Zhang; Pan Lin; Huqing Shi; Dost Öngür; Randy P Auerbach; Xiaosheng Wang; Shuqiao Yao; Xiang Wang
Journal:  Brain Imaging Behav       Date:  2016-09       Impact factor: 3.978

10.  Dissociable influences of reward motivation and positive emotion on cognitive control.

Authors:  Kimberly S Chiew; Todd S Braver
Journal:  Cogn Affect Behav Neurosci       Date:  2014-06       Impact factor: 3.282

View more
  7 in total

1.  Negative Symptom Therapeutics.

Authors:  William T Carpenter; Robert W Buchanan
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

2.  Social and nonsocial reward moderate the relation between autism symptoms and loneliness in adults with ASD, depression, and controls.

Authors:  Gloria T Han; Andrew J Tomarken; Katherine O Gotham
Journal:  Autism Res       Date:  2019-03-02       Impact factor: 5.216

3.  Sex differences in effort-related decision-making: role of dopamine D2 receptor antagonism.

Authors:  Emily L Errante; Marilyn Chakkalamuri; Oreoluwa I Akinbo; Samantha E Yohn; John D Salamone; Leslie Matuszewich
Journal:  Psychopharmacology (Berl)       Date:  2021-02-15       Impact factor: 4.530

4.  Natural Language Processing: Its Potential Role in Clinical Care and Clinical Research.

Authors:  Stephen R Marder
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

Review 5.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

6.  What gets in the way of social engagement in schizophrenia?

Authors:  Lauren P Weittenhiller; Megan E Mikhail; Jasmine Mote; Timothy R Campellone; Ann M Kring
Journal:  World J Psychiatry       Date:  2021-01-19

Review 7.  Primary and Secondary Negative Symptoms in Schizophrenia.

Authors:  Sergey N Mosolov; Polina A Yaltonskaya
Journal:  Front Psychiatry       Date:  2022-01-03       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.